
|Videos|October 17, 2018
Combination Encorafenib Plus Binimetinib in Patients With Melanoma
Author(s)Paolo A. Ascierto, MD
Paolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.
Advertisement
Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how results from the COLUMBUS trial affect the treatment landscape for patients withBRAF-mutant melanoma.
Ascierto recommends choosing the combination encorafenib (Braftovi) plus binimetinib (Mektovi). While the efficacy appeared similar to other treatments, encorafenib may be considered the “best” BRAF inhibitor.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5


































